MWNA
TGTX icon

Marshall Wace North America’s TG Therapeutics TGTX Stock Holding History

Marshall Wace North America’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,815
Closed -$510K – 1777
2020
Q4 		$510K Buy
+9,815
New +$332K ﹤0.01% 1082

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Marshall Wace North America's TGTX Position: Q1 2021 in Review

Marshall Wace North America sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 9,815 shares — an estimated $510K sold.

Marshall Wace North America first reported a position in TGTX in Q4 2020 and held it in 1 quarter. The position peaked at $510K in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

  • Marshall Wace North America reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 9,815 TG Therapeutics shares in Q1 2021, an estimated $510K.
  • Marshall Wace North America first reported a position in TG Therapeutics in Q4 2020 and held it in 1 quarter.
  • Marshall Wace North America's TG Therapeutics position peaked at $510K in Q4 2020.
  • 240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.